SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-23-007207
Filing Date
2023-10-17
Accepted
2023-10-17 08:00:11
Documents
14
Period of Report
2023-10-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT cns_8k.htm   iXBRL 8-K 47706
2 FORM OF INDUCEMENT WARRANT cns_ex0401.htm EX-4.1 110553
3 FORM OF INDUCEMENT LETTER cns_ex1001.htm EX-10.1 67417
  Complete submission text file 0001683168-23-007207.txt   449234

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cnsp-20231016.xsd EX-101.SCH 3018
5 XBRL LABEL FILE cnsp-20231016_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE cnsp-20231016_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3418
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 231328468
SIC: 2834 Pharmaceutical Preparations